Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response

[1]  B. O'connor,et al.  Comparison of incremental and bolus dose inhaled allergen challenge in asthmatic patients , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[2]  P. Foster.  Allergic networks regulating eosinophilia. , 1999, American journal of respiratory cell and molecular biology.

[3]  M. Lampinen,et al.  The role of interleukin‐5, interleukin‐8 and RANTES in the chemotactic attraction of eosinophils to the allergic lung , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[4]  R. Duranti,et al.  Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. , 1999, The Journal of allergy and clinical immunology.

[5]  H. Jansen,et al.  The late asthmatic response is associated with baseline allergen‐specific proliferative responsiveness of peripheral T lymphocytes in vitro and serum interleukin‐5 , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  Y. Qin,et al.  TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma. , 1999, American journal of respiratory and critical care medicine.

[7]  R. Solari,et al.  INTERLEUKIN-5 AND THE INTERLEUKIN-5 RECEPTOR : TARGETS FOR DRUG DISCOVERY IN ASTHMA , 1999 .

[8]  P. Foster,et al.  A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. , 1998, Journal of immunology.

[9]  P. Barnes,et al.  Allergen-induced early and late asthmatic responses are not affected by inhibition of endogenous nitric oxide. , 1998, American journal of respiratory and critical care medicine.

[10]  A. Niimi,et al.  Eosinophilic inflammation in cough variant asthma. , 1998, The European respiratory journal.

[11]  H. Xu,et al.  Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics. , 1998, American journal of respiratory and critical care medicine.

[12]  V. Brusasco,et al.  Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. , 1998, American journal of respiratory and critical care medicine.

[13]  S. Durham,et al.  Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. , 1997, American journal of respiratory and critical care medicine.

[14]  H. Boushey,et al.  The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. , 1997, American journal of respiratory and critical care medicine.

[15]  S. Durham,et al.  Effect of cyclosporin A on the allergen-induced late asthmatic reaction. , 1997, Thorax.

[16]  J. J. Klein,et al.  Compliance with inhaled medication and self-treatment guidelines following a self-management programme in adult asthmatics. , 1997, The European respiratory journal.

[17]  R. Djukanović,et al.  Cell infiltration, ICAM-1 expression, and eosinophil chemotactic activity in asthmatic sputum. , 1997, American journal of respiratory and critical care medicine.

[18]  P. Weller.  Human eosinophils. , 1997, The Journal of allergy and clinical immunology.

[19]  M. Jordana,et al.  Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. , 1996, American journal of respiratory and critical care medicine.

[20]  P. Foster,et al.  Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model , 1996, The Journal of experimental medicine.

[21]  P. O'Byrne,et al.  Reproducibility of allergen-induced early and late asthmatic responses. , 1995, The Journal of allergy and clinical immunology.

[22]  D. Proud,et al.  Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. , 1995, The Journal of clinical investigation.

[23]  R. Egan,et al.  Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. , 1993, The American review of respiratory disease.

[24]  A. Stewart,et al.  Airway wall remodelling in asthma: a novel target for the development of anti-asthma drugs. , 1993, Trends in pharmacological sciences.

[25]  Kevin Giblin,et al.  Tolerance to the nonbronchodilator effects of inhaled β2-agonists in asthma: O'Connor BJ, Aikman SL, Barnes PJ N Engl J Med 327:1204–1208 Oct 22, 1992 , 1993 .

[26]  I. van Ark,et al.  Effect of anti-IL-5 and IL-5 on airway hyperreactivity and eosinophils in guinea pigs. , 1993, The American review of respiratory disease.

[27]  I. Chapman,et al.  The relationship between inflammation and hyperreactivity of the airways in asthma , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[28]  S. Durham,et al.  CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy. , 1993, The American review of respiratory disease.

[29]  P. Barnes,et al.  Tolerance to the Nonbronchodilator Effects of Inhaled β2-Agonists in Asthma , 1992 .

[30]  C. Sanderson.  Interleukin-5, Eosinophils, and Disease , 1992 .

[31]  J. Lötvall,et al.  Effect of dexamethasone and cyclosporin A on allergen-induced airway hyperresponsiveness and inflammatory cell responses in sensitized Brown-Norway rats. , 1992, The American review of respiratory disease.

[32]  C. Sanderson,et al.  Interleukin-5, eosinophils, and disease. , 1992, Blood.

[33]  C. Dollery,et al.  Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects , 1991, The Lancet.

[34]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.